Don't Go With The Flow: New Perspectives On Fetal Intervention For Lower Urinary Tract Obstruction.

Authors

Abstract

Fetal intervention for lower urinary tract obstruction (LUTO) has advanced more slowly than other areas of fetal surgery. Thirteen years after the PLUTO trial, three core problems remain unresolved. Firstly, prenatal ultrasound diagnosis is not accurate enough to reliably distinguish LUTO from non-obstructive megacystis. Secondly, selection criteria for vesico-amniotic shunting (VAS) remain poorly defined, since the developmental impact of bladder outlet obstruction is highly variable between fetuses. Thirdly, outcome reporting is inconsistent, with "perinatal survival" obscuring the true long-term picture for posterior urethral valves (PUV). The introduction of the low-profile SOMATEX© shunt has enabled VAS from as early as 11 weeks' gestation. A recent prospective cohort study (IUS1st) of first-trimester shunting for severe megacystis reported 73% perinatal survival and largely preserved renal function at one year, but also revealed striking urological morbidity, with over half of infants requiring diversion procedures for urethral hypoplasia. Whether this reflects a consequence of urethral bypass throughout gestation, or simply the natural history of the underlying disease, remains unresolved - underscoring the continued need for a control group. Looking ahead, more selective patient stratification may come from combining ultrasound with fetal MRI, fetal urinary peptidomic signatures, and AI-assisted image analysis, while next-generation, pressure-limiting shunts such as the Vortex© device aim to preserve physiological bladder cycling rather than fully defunctionalising the bladder. An international collaborative registry, rather than a further randomised controlled trial, may offer the most realistic route to answering these questions.

Tags

Topics